Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder.

Magalhães PV, Dean OM, Bush AI, Copolov DL, Weisinger D, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):132-5. doi: 10.1016/j.pnpbp.2011.11.011.

PMID:
22212173
2.

N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial.

Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI.

Biol Psychiatry. 2008 Sep 15;64(6):468-75. doi: 10.1016/j.biopsych.2008.04.022.

PMID:
18534556
3.

A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania.

Magalhães PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M.

Aust N Z J Psychiatry. 2013 Jun;47(6):564-8. doi: 10.1177/0004867413481631.

PMID:
23493756
4.

N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial.

Magalhães PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M.

J Affect Disord. 2011 Mar;129(1-3):317-20. doi: 10.1016/j.jad.2010.08.001.

PMID:
20800897
5.

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.

Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI.

Biol Psychiatry. 2008 Sep 1;64(5):361-8. doi: 10.1016/j.biopsych.2008.03.004.

PMID:
18436195
6.

Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo.

Das P, Tanious M, Fritz K, Dodd S, Dean OM, Berk M, Malhi GS.

Aust N Z J Psychiatry. 2013 Apr;47(4):347-54. doi: 10.1177/0004867412474074.

PMID:
23341476
7.

N-acetylcysteine for major depressive episodes in bipolar disorder.

Magalhães PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M.

Rev Bras Psiquiatr. 2011 Dec;33(4):374-8.

8.

Effects of N-acetyl cysteine on cognitive function in bipolar disorder.

Dean OM, Bush AI, Copolov DL, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M.

Psychiatry Clin Neurosci. 2012 Oct;66(6):514-7. doi: 10.1111/j.1440-1819.2012.02392.x.

9.

The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial.

Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, Cobb H, Bush AI, Schapkaitz I, Dodd S, Malhi GS.

J Affect Disord. 2011 Dec;135(1-3):389-94. doi: 10.1016/j.jad.2011.06.005.

PMID:
21719110
10.

Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting.

Berk M, Jeavons S, Dean OM, Dodd S, Moss K, Gama CS, Malhi GS.

CNS Spectr. 2009 Jul;14(7):357-60.

PMID:
19773711
11.

Medical and psychiatric comorbidities among elderly individuals with bipolar disorder: a literature review.

Lala SV, Sajatovic M.

J Geriatr Psychiatry Neurol. 2012 Mar;25(1):20-5. doi: 10.1177/0891988712436683. Review.

PMID:
22467842
12.

Improving medical and psychiatric outcomes among individuals with bipolar disorder: a randomized controlled trial.

Kilbourne AM, Post EP, Nossek A, Drill L, Cooley S, Bauer MS.

Psychiatr Serv. 2008 Jul;59(7):760-8. doi: 10.1176/appi.ps.59.7.760.

PMID:
18586993
13.
14.

Medical comorbidity in women and men with bipolar disorders: a population-based controlled study.

Carney CP, Jones LE.

Psychosom Med. 2006 Sep-Oct;68(5):684-91.

PMID:
17012521
15.

Effect of N-acetylcysteine on cardiac injury and oxidative stress after abdominal aortic aneurysm repair: a randomized controlled trial.

Mahmoud KM, Ammar AS.

Acta Anaesthesiol Scand. 2011 Sep;55(8):1015-21. doi: 10.1111/j.1399-6576.2011.02492.x.

PMID:
22092168
16.

Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression.

Dean OM, Turner A, Malhi GS, Ng C, Cotton SM, Dodd S, Sarris J, Samuni Y, Tanious M, Dowling N, Waterdrinker A, Smith D, Berk M.

Rev Bras Psiquiatr. 2015 Jan-Mar;37(1):3-12. doi: 10.1590/1516-4446-2013-1341.

17.

Illness burden and medical comorbidity in the Systematic Treatment Enhancement Program for Bipolar Disorder.

Magalhães PV, Kapczinski F, Nierenberg AA, Deckersbach T, Weisinger D, Dodd S, Berk M.

Acta Psychiatr Scand. 2012 Apr;125(4):303-8. doi: 10.1111/j.1600-0447.2011.01794.x.

PMID:
22098628
18.

A prospective study of the impact of comorbid medical disease on bipolar disorder outcomes.

Pirraglia PA, Biswas K, Kilbourne AM, Fenn H, Bauer MS.

J Affect Disord. 2009 Jun;115(3):355-9. doi: 10.1016/j.jad.2008.09.020.

PMID:
18930558
19.

Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression.

Simon GE, Bauer MS, Ludman EJ, Operskalski BH, Unützer J.

J Clin Psychiatry. 2007 Aug;68(8):1237-45.

PMID:
17854249
20.

Psychiatric and medical comorbidities of bipolar disorder.

Krishnan KR.

Psychosom Med. 2005 Jan-Feb;67(1):1-8. Review.

PMID:
15673617
Items per page

Supplemental Content

Support Center